.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04B_DrugsForTreatmentOfLepra.J04BA01_Clofazimine.Clofazimine_1 .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04B_DrugsForTreatmentOfLepra.J04BA01_Clofazimine.Clofazimine_1| name: | Clofazimine_1 |
| ATC code: | J04BA01_1 | route: | oral |
| n-compartments | 1 |
Clofazimine is a riminophenazine antibiotic primarily used for the treatment of leprosy (Hansen's disease), especially for multibacillary forms and as part of multidrug therapy. It is also occasionally used off-label for some mycobacterial infections. Clofazimine is approved and used in several countries but is not approved for all mycobacterial infections. Its use is limited due to side effects such as skin discoloration and gastrointestinal symptoms.
Multiple-dose, steady-state PK in leprosy patients.
Zhang, CX, et al., & Arnold, SLM (2022). Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis. Antimicrobial agents and chemotherapy 66(1) e0156021–None. DOI:10.1128/AAC.01560-21 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34748385
Stadler, JAM, et al., & Wasserman, S (2023). Clofazimine for the treatment of tuberculosis. Frontiers in pharmacology 14 1100488–None. DOI:10.3389/fphar.2023.1100488 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36817137
Zhang, CX, et al., & Arnold, SLM (2024). Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics. CPT: pharmacometrics & systems pharmacology 13(3) 410–423. DOI:10.1002/psp4.13092 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38164114